• Combining Lenovo’s global resources with LPS’ local expertise, the Next-Gen ecosystem covers four key domains: application software, office automation, cybersecurity, and infrastructure
• As Hong Kong’s premier systems integrator and application developer, LPS delivers full-stack capabilities spanning front-end, middleware, and back-end technologies

HONG KONG, Nov. 10, 2025 /PRNewswire/ — Lenovo PCCW Solutions (LPS) announces the establishment of the “Next-Gen IT Ecosystem” at its recent Go-Global Ceremony. The initiative brings together 18 leading Next-Gen IT companies to drive digital transformation and sustainable innovation for enterprises in Hong Kong and Asia Pacific. This move aligns with the Hong Kong SAR Government’s latest Policy Address initiative to deepen technology cooperation between Chinese Mainland and international markets, further consolidating Hong Kong’s position as an international innovation and technology hub.

Built on the core principle of “indigenous innovation,” the ecosystem leverages Lenovo’s powerful global network and LPS’ localized expertise to integrate multiple independently developed technology brands. It delivers comprehensive full-stack solutions across four key domains – application software, office automation, cybersecurity, and infrastructure – supporting enterprises’ end-to-end transformation needs from strategic consulting to technology implementation.

As Hong Kong’s premier systems integrator and application developer, LPS is one of the technology service providers with the most Next-Gen IT certifications, holding over 240. With a 4,000-strong technical team and extensive hands-on experience in application modernization, LPS excels at delivering digital transformation services that seamlessly connect front-end applications, middleware integration, and back-end infrastructure. Through rigorous quality and risk management mechanisms, LPS ensures system stability, compliance, reliability, and business continuity.

• Application Software: LPS partners with Yonyou, FanRuan, Sensors Data, ShareCRM, OceanBase, Kingbase, and GBase to deliver ERP, business intelligence, and database migration solutions that integrate AI and data analytics, enhancing enterprise decision-making and management efficiency.
• Office Automation: Collaborating with FileZ, Seeyon, and Coremail to promote smart collaboration and process automation, improving collaborative efficiency.
• Cybersecurity: Working with 360 Tech, Leagsoft, Qi An Xin (QAX), VenusTech, and Sangfor to build comprehensive security systems with AI threat detection and proactive defense capabilities, strengthening cyber resilience.
• Infrastructure: Integrating technologies from Cloudwise, Aishu, and Kylin to provide stable and highly scalable AIOps intelligent operations, data backup, and operating system support.

Fan Ho, Executive Director and General Manager, AP Solutions and Services Group, Lenovo, stated: “Lenovo has committed to building an open technology ecosystem. Through Lenovo Capital and Incubator Group (LCIG), we have invested in and supported over 300 innovative start-ups covering key areas such as AI, semiconductors, and advanced manufacturing. The newly established Next-Gen IT Ecosystem represents a crucial step in combining local technology integration capabilities with global presence. Leveraging Lenovo’s sales, service, and partner network spanning 180 markets, we will provide ecosystem members with comprehensive support from technology validation and scenario implementation to international expansion.”

Vincent Leung, Head of Ecosystem, LPS, said: “We believe that under an open collaboration framework, technological innovation can create stronger synergies. The core spirit of the Next-Gen IT Ecosystem is ‘co-building, co-creating, and co-sharing’ – we don’t just integrate products, but also facilitate technology interoperability and collaborative solution development. Moving forward, we will continue to attract quality partners locally and regionally to deepen technology exchange and industry integration, bringing customers solutions that are better aligned with market needs and deliver greater economic value.”

Looking ahead, LPS will continue to enhance the ecosystem framework and encourage more partners to join in building an open, trusted, and efficient technology collaboration platform, helping enterprises achieve secure and efficient digital transformation.

For more information about the “Next-Gen IT Ecosystem,” please visit:
https://www.lpstech.com/site/en/service/next-gen-it-innovation/overview.html

About Lenovo PCCW Solutions (LPS)

LPS is a leading IT and technology solutions provider in the Asia Pacific region. We partner with governments and enterprises to achieve digital transformation excellence, driving business growth through our market-leading solutions and industry best practices. As a proud member of Lenovo Group, we have unlocked new synergies with Lenovo’s global reach and technological capabilities, focusing on AI, data practice, cloud and cybersecurity. With our 4,000+ team of domain experts and a strong network of ecosystem partners, LPS is committed to providing cutting-edge AI-powered solutions and data best practices to enable organizations to excel in their digital journey.

CHENGDU, China, Nov. 10, 2025 /PRNewswire/ — From November 6 to 9, the 2025 Chinese Congress on Holistic Integrative Oncology (CCHIO) was held in Kunming, Yunnan. This conference was jointly organized by the Chinese Anti-Cancer Association (CACA), the Tengchong Science Forum Organizing Committee Office, the World Association for Integrative Oncology (WAIO), and the China Institute for Integrative Medicine Development Strategy. Academicians, experts, and scholars from across the nation gathered to focus on innovations in cancer diagnosis and treatment while sharing scientific breakthroughs. At the conference, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company,” 6990.HK) presented results from multiple clinical studies on its TROP2 ADC sacituzumab tirumotecan (sac-TMT) as oral presentations.

KL264-01/MK-2870-001

On November 7, Professor Sheng Jindong from Tianjin Cancer Hospital presented oral results on the efficacy and safety of sacituzumab tirumotecan (sac-TMT) monotherapy for locally advanced or metastatic endometrial cancer (EC) in a Phase II study at the conference. The endometrial carcinoma (EC) cohort in this study enrolled a total of 158 patients, with 114 patients assigned to the sac-TMT 4 mg/kg group and 44 patients to the sac-TMT 5 mg/kg group.

At data cutoff (May 21, 2025), median (range) follow-up was 11.7 months in the 4 mg/kg group and 21.8 months in the 5 mg/kg group. Confirmed objective response rate (ORR) was 30.7% and 34.1% in the 4 mg/kg and 5 mg/kg groups; all responses were partial response (PR). Confirmed and unconfirmed ORR was 35.1% and 36.4% in the 4 mg/kg and 5 mg/kg groups. Median duration of response (DOR) was 9.3 months and 8.7 months in the 4 mg/kg and 5 mg/kg groups. Median progression free survival (PFS) was 6.0 months and 7.3 months in the 4 mg/kg and 5 mg/kg groups.

Grade ≥3 treatment-related AEs (TRAEs) occurred in 59 patients (51.8%) and 34 patients (77.3%) in the 4 mg/kg and 5 mg/kg groups respectively; Treatment-related AEs that led to treatment discontinuation was 2 and 1 patient in each group, respectively.

In patients with advanced EC, sac-TMT monotherapy showed promising antitumor activity in the ≥2L advanced/metastatic setting and manageable safety. Both the 4 mg/kg and 5 mg/kg groups exhibited manageable safety and tolerability profiles consistent with the known safety characteristics of sac-TMT. These data led to initiation of two ongoing global Phase 3 studies of sac-TMT 4 mg/kg Q2W in advanced EC, which were sponsored and led by MSD.

OptiTROP-Lung03

On November 8, Professor Fang Wenfeng from the Cancer Center of Sun Yat-sen University delivered an oral presentation at the conference on preliminary results from a Phase II study evaluating sac-TMT in treating locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations in previously treated patients. As of Dec 01, 2024, 42 patients were enrolled, including 23 patients with EGFR uncommon non-ex20ins mutations and 19 patients with EGFR ex20ins. Patients received sac-TMT 5 mg/kg Q2W until disease progression or unacceptable toxicity. After a median follow-up of 9.9 months, the ORR was 35.7% (15/42, 3 pending confirmation). The disease control rate (DCR) was 85.7%. Responses were durable with the median duration of response (mDoR) not yet reached, and the 6-month DoR rate was 90.9%. The median progression-free survival (mPFS) was 9.5 months (95% CI: 5.6, 10.9).

In the subset of patients with uncommon non-ex20ins, the ORR was 34.8% (8/23, 1 pending confirmation); the mPFS was 10.9 months (95% CI: 5.6, NE). In the subset of patients with ex20ins, the ORR was 36.8% (7/19, 2 pending confirmation); the mPFS was 9.0 months (95% CI: 2.4, NE). Grade ≥3 treatment-related adverse events occurred in 52.4% of pts. No TRAE led to treatment discontinuation or death. No cases of interstitial lung disease/pneumonitis were reported.

Sac-TMT monotherapy demonstrated promising clinical activity with a manageable safety profile in previously treated advanced NSCLC patients with uncommon EGFR mutations. These findings warrant further investigation of sac-TMT as a potential therapy for this population.

OptiTROP-Lung01

Professor Fang Wenfeng also presented results from the non-squamous cohort in the Phase II study evaluating the combination of sac-TMT and tagitanlimab (anti-PD-L1) as first-line therapy for advanced NSCLC during the oral presentation session. As of Dec 30, 2024, 81 patients with non-squamous histology were enrolled. Patients receive sac-TMT (5 mg/kg Q3W or Q2W) plus tagitanlimab (1200 mg Q3W or 900 mg Q2W) until disease progression or unacceptable toxicity. After median follow-up of 17.1 months, the confirmed ORR was 59.3%; The DCR was 91.4%; mDOR was 16.5 months (95% CI: 11.7, 22.1); mPFS was 15.0 months (95% CI: 10.8, 24.8). Among pts with PD-L1 TPS< 1%, the confirmed ORR was 47.1%; mPFS was 12.4 months (95%CI: 7.6, 15.4); while for patients with PD-L1 TPS≥ 1%, the confirmed ORR was 68.1%; mPFS was 17.8 months (95%CI: 14.5, NE). Among patients with PD-L1 TPS≥ 50%, the confirmed ORR was 77.8%; mPFS was 17.8 months (95% CI: 10.8, NE). No TRAE led to treatment discontinuation or death.

Sac-TMT in combination with tagitanlimab demonstrated promising antitumor activity in treatment-naive advanced non-squamous NSCLC. The durable clinical activities were observed regardless of PD-L1 expression. This combination therapy showed a tolerable safety profile based on known profiles of the individual agents, with no new safety signals observed.

Currently, two Phase 3 registrational studies of sac-TMT, namely (i) sac-TMT in combination with pembrolizumab (KEYTRUDA^®1) versus pembrolizumab for first-line treatment of patients with PD-L1 positive locally advanced or metastatic NSCLC, and (ii) sac-TMT in combination with pembrolizumab versus chemotherapy combined with pembrolizumab as first-line treatment for patients with PD-L1 negative locally advanced or metastatic non-squamous NSCLC are in progress.

With the goal of addressing patients’ urgent clinical needs, Kelun-Biotech has initiated over 30 clinical studies across multiple disease areas including lung cancer, breast cancer, and gynecological tumors. Leveraging its proprietary ADC and novel DC platform, OptiDC™, the Company will continue developing innovative drugs with significant clinical value. This commitment aims to further enhance patient outcomes and contribute corporate strength to advancing the Healthy China initiative.

About Sac-TMT 

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macau, and Taiwan).

To date, three indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting), EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy and EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy. Sac-TMT is the first TROP2 ADC drug approved for marketing in lung cancer globally. In addition, the new indication application for sac-TMT for the treatment of adult patients with unresectable locally advanced, metastatic hormone receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting was accepted by the Center for Drug Evaluation of the NMPA, and was included in the priority review and approval process.

As of today, the Company has initiated 9 registrational clinical studies in China. MSD has initiated 15 ongoing Phase Ⅲ global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 4 projects have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. The company has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://kelun-biotech.com/.

References:
1. Pembrolizumab (KEYTRUDA^®) is a registered trademark of Merck Sharp & Dohme LLC (MSD), a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

SINGAPORE, Nov. 10, 2025 /PRNewswire/ — Following two highly successful years as the premier retail event for retail leaders, innovators and solutions providers across Asia Pacific, NRF 2026: Retail’s Big Show Asia Pacific is returning to Singapore on June 2-4, 2026, bringing together more than 11,000 retail professionals from 80 countries for three days of transformative learning, discovery, and networking.

The 2026 event theme “The Next Now” reflects how the APAC region is on the brink of massive transformation, driven by a rapidly expanding middle class projected to reach 3.5 billion consumers within the next decade. This demographic surge is accelerating retailers’ investments in technology and innovation to meet growing consumer demand. At NRF 2026 APAC, retailers will explore how to embrace this industry momentum and seize opportunities for success.

“APAC retail is setting the pace, and the world is looking to this region for what’s coming next,” said Ryf Quail, Managing Director, APAC, Comexposium. “Under ‘The Next Now’ theme, NRF 2026 APAC will showcase how retailers are turning data, design, and digital innovation into the blueprint for the future of commerce.”

Step into “The Next Now” of retail innovation

Spanning 23,000 square metres across two floors at the Marina Bay Sands Convention Centre, the three-day conference will feature 11 keynote sessions from global C-suite leaders, 18 breakout sessions, and 12 invite-only roundtables, covering 15 topics impacting retailers today, including:

• Agentic AI and commerce – understanding AI’s latest iteration
• AI’s impact on retail – vertical transcendence and organisational transformation
• Hyperexperientialism – the return of emotionally immersive branding
• Cross-border commerce – complexity incarnate

New and returning show features include:

• Foodservice Innovation Zone (NEW!) – Exploring the fusion of food and retail experiences.
• Innovators Showcase – 40% bigger than last year’s, featuring 42 of the world’s top retail innovations, all completely new for 2026.
• NRF APAC Partner Lounge (NEW!) – An exclusive zone connecting retailers with industry partners, accelerators and market-entry experts.
• Country Pavilions representing Vietnam, Australia, Korea, France, China, and Singapore.

Delegates can look forward to expanded networking opportunities throughout the show — from curated meetups and exclusive networking lounges to daily happy hours designed to turn meaningful conversations into lasting business connections.

NRF APAC CEO Club, a prestigious invite-only forum limited to 100 retail CEOs, will also return to offer an intimate environment for top leaders to exchange insights, debate strategies, and forge regional partnerships.

A global stage for a regional powerhouse

“APAC retail is evolving faster than anywhere else in the world,” said Samuel Kim, Vice Chairman and Group CEO, Lotte Retail. “NRF 2026 APAC celebrates that dynamism — it’s where ideas become action, and where the next wave of retail transformation begins.”

NRF 2026 APAC is supported by a powerhouse advisory board featuring retail leaders such as Nandita Sinha (Myntra), Eva Baquedano (Loewe), Jonathan Burks (Coupang), and Rio Popeye Inaba (Suntory).

Available starting December 10, 2025, the All-Access Pass unlocks the full NRF APAC experience. Learn directly from the world’s leading retail innovators, gain actionable insights to accelerate your business, and experience the future of retail firsthand across three days of transformative content and connections. 

The first 100 people to register will enjoy an additional US$749 off their event pass plus travel rebates up to US$200.

About NRF 2026: Retail’s Big Show Asia Pacific

Retail’s most important event in Asia Pacific takes place in Singapore from June 2-4, 2026. The Asia Pacific edition brings together retail industry leaders from across the region to collaborate on a Pan Asia Pacific stage, home of the world’s fastest growing markets. Retail professionals can gain inspiration from top retail leaders over a three-day conference, an all-encompassing Expo featuring the latest retail solutions, as well as experience the latest innovations and breakthrough technologies available in the market.

SINGAPORE, Nov. 10, 2025 /PRNewswire/ — Alarm.com (Nasdaq: ALRM), the leading platform for intelligently connected properties, will demonstrate its unified smart security ecosystem at The Security Event Asia 2025, showing how the company helps organizations bridge legacy systems with modern, cloud-managed technology. The showcase marks a significant step in Alarm.com’s continued investment across the Asia-Pacific region, where smart infrastructure and digitalization are reshaping the security landscape.

Across ASEAN markets, many businesses face the challenge of merging traditional alarm, video and access control systems with new solutions. These separate systems often create inefficiencies and limit scalability. Alarm.com’s One Unified Platform eliminates this barrier by connecting multiple technologies within a single cloud environment. With the launch of innovative solutions like the Alarm.com Universal Communicator (AUC), the company is enabling service providers and enterprises to modernize their operations without the need for full system replacement or disruptive overhauls.

“At a time when businesses in Southeast Asia are embracing digital transformation, we’re helping security providers modernize their services and deliver greater value through an intelligent, unified platform,” said Ian Law, Director of Business Development – Asia-Pacific. “Our mission is to make smart security straightforward and dependable for every type of property, giving both our partners and their customers true peace of mind.”

The Alarm.com platform brings together intrusion detection, video surveillance, access control and automation in one connected system that can be managed remotely via app or web dashboard. Users can view live and recorded video, adjust settings or control access in real time. Built-in analytics filter out irrelevant activity, distinguishing between people, vehicles and animals to reduce false notifications and improve response times. For commercial customers, cloud-based access management provides flexibility. Administrators can issue or revoke mobile credentials instantly, ensuring secure control across multiple locations.

More than just a front-end experience, Alarm.com’s technology is supported by one of the most robust and intelligent back-end systems in the industry. This powerful infrastructure allows dealers to activate accounts, analyze data trends and configure settings remotely, helping them operate more efficiently and profitably. Alarm.com’s investment in this area reflects its firm commitment to dealer growth.

At Booth #2619 in the Sands Expo & Convention Center, Alarm.com will present several innovations designed for the APAC market. The Alarm.com Universal Communicator (AUC) enables legacy alarm panels to connect directly to the Alarm.com platform, offering an affordable upgrade path for markets moving away from 2G, 3G and legacy network infrastructure. The company will also highlight Climax Panel Support, which expands compatibility and simplifies installation, and the Enterprise Security Console, which gives businesses centralized oversight of multiple sites through a single management interface. Alarm.com’s Integrated Video and Analytics capability will demonstrate how cloud-based intelligence and visual verification are helping security providers deliver faster, more informed responses.

During the Safety & Security Asia XForum at the event, Ian Law will discuss how intelligent technology is reshaping the next generation of property protection. His sessions include:

“AI in Security: Real Value Now and Strategic Potential Ahead”
“Beyond the Camera: Video’s Expanding Role in Security and Business Intelligence”
“Access Control Transformation: Unlocking Value Beyond Keeping Bad People Out”

These presentations will offer insights into how artificial intelligence, cloud infrastructure and enterprise-level management are influencing operational efficiency and security strategy in the region.

Through subsidiaries such as EBS, CHeKT and OpenEye, Alarm.com continues to expand its global ecosystem, advancing connected video, AI-based monitoring and remote management technologies. Each innovation is designed to help professional partners deliver scalable solutions that improve performance and reduce complexity for end users. This integrated ecosystem underlines Alarm.com’s role as a “technological Swiss Army knife” — an adaptable platform that connects dealers, data and end users through a single intelligent interface.

With millions of active systems worldwide, Alarm.com’s continued expansion in Singapore and dedication to the whole ASEAN region reinforces its purpose of connecting peace of mind. For dealers, peace of mind means enhanced profitability and a stronger reputation with customers. For end users, it means a safer, more efficient environment, whether protecting a business or a home. By enabling partners to grow through data intelligence, scalability and reliable service, Alarm.com continues to shape a future defined by intelligent solutions that turn information into confidence and confidence into growth.

About Alarm.com

Alarm.com is the leading platform for the intelligently connected property, relied upon by millions of consumers and businesses worldwide. The platform integrates security, video, access control, intelligent automation, and energy management through a global network of professional service providers. Alarm.com’s common stock is traded on Nasdaq under the ticker symbol ALRM. Visit alarm.com or https://home.alarm.com/apac/ for regional inquiries.